Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000243:Adenosine Deaminase / Q000172:deficiency; D058892:Adenosine Deaminase Inhibitors; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003070:Coformycin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003839:Deoxyadenosines / Q000378:metabolism; D006801:Humans; D007399:Interphase / Q000187:drug effects; D007938:Leukemia / Q000188:drug therapy*; D008231:Lymphopenia / Q000139:chemically induced; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D015649:Pentostatin; D011687:Purines / Q000378:metabolism*; D012263:Ribonucleosides / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000201:enzymology*
D058892:Adenosine Deaminase Inhibitors; D003839:Deoxyadenosines; D011687:Purines; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin; C010192:9-(2-hydroxy-3-nonyl)adenine; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase; D000225:Adenine